Haizheng Pharmaceutical announced that the clinical trial application for HS387 tablets declared by the company has been approved by the US FDA, and clinical trials can be carried out in the US. This drug is a selective KIF18A inhibitor independently developed by the company. It is intended to be used to treat advanced solid tumors. It has previously been approved for clinical trials by the State Drug Administration. Currently, many KIF18A inhibitors at home and abroad have entered the clinical development stage, and no drugs have been marketed. However, it is still necessary to carry out a series of clinical trials before the drug is approved for marketing. It will have little impact on the company's operations in the short term, and investors are reminded to be aware of the risks.

Haizheng Pharmaceutical announced that the clinical trial application for HS387 tablets declared by the company has been approved by the US FDA, and clinical trials can be carried out in the US. This drug is a selective KIF18A inhibitor independently developed by the company. It is intended to be used to treat advanced solid tumors. It has previously been approved for clinical trials by the State Drug Administration. Currently, many KIF18A inhibitors at home and abroad have entered the clinical development stage, and no drugs have been marketed. However, it is still necessary to carry out a series of clinical trials before the drug is approved for marketing. It will have little impact on the company's operations in the short term, and investors are reminded to be aware of the risks.